Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Geron Corporation

Optimizing SG&A Costs: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Alpine Immune Sciences, Inc. and Geron Corporation have taken different paths in optimizing these costs.

From 2014 to 2023, Alpine Immune Sciences, Inc. demonstrated a steady increase in SG&A expenses, starting at approximately $2.3 million and reaching $22.2 million. This represents a nearly tenfold increase, reflecting their aggressive growth strategy. In contrast, Geron Corporation's SG&A expenses surged from $16.8 million to $69.1 million, a fourfold rise, indicating a more substantial investment in administrative functions.

While both companies have seen significant increases, Alpine's more gradual rise suggests a potentially more efficient cost management approach. Investors and industry analysts should consider these trends when evaluating the financial strategies of these biotech players.